Kura Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for the treatment of cancer and other diseases with significant unmet medical need. The company operates primarily in the oncology and hematology sectors, leveraging its expertise in small molecule therapeutics to target dysregulated proteins and cellular pathways that drive disease progression. Kura Oncology aims to improve patient outcomes by matching targeted therapeutics to patients most likely to benefit, using a strategy grounded in molecular and genomic profiling.

The company generates revenue primarily through the commercial sale of its approved product, KOMZIFTI, which is marketed in the United States for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) harboring a susceptible NPM1 mutation. Revenue is derived from product sales under a co-promotion agreement with Kyowa Kirin, under which Kura Oncology leads commercial strategy and manufacturing in the United States and shares equally in profits and losses from commercialization activities. Additionally, the company may receive milestone payments, royalties, and profit-sharing under its license and collaboration agreements, including those with Kyowa Kirin and Mirati/BMS, as its pipeline advances.

The company operates through the following segments:

• Menin Inhibitor Program: This segment focuses on the development and commercialization of small molecule inhibitors targeting the menin-KMT2A protein-protein interaction. The lead product in this segment is ziftomenib, marketed as KOMZIFTI, which received FDA approval in November 2025 for relapsed or refractory NPM1-mutated AML. The segment also includes the evaluation of next-generation menin inhibitors such as KO-7246 for potential use in diabetes, cardiometabolic disorders, and solid tumor indications.

• Farnesyl Transferase Inhibitor (FTI) Program: This segment is dedicated to the development of FTIs for use in combination with targeted therapies in solid tumor indications. The lead product candidate in this segment is darlifarnib, which is being evaluated in combination with cabozantinib in renal cell carcinoma, adagrasib in KRAS G12C-mutated non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma, and other targeted agents. The segment also includes tipifarnib, a first-generation FTI, which has been studied in combination with alpelisib in head and neck squamous cell carcinoma.

Kura Oncology positions itself as a leader in precision medicine, particularly in the menin inhibitor space, where KOMZIFTI is the first and only FDA-approved once-daily oral menin inhibitor for the treatment of NPM1-mutated AML. The company differentiates itself through a focus on biomarker-driven patient selection, combination therapies with standards of care, and a pipeline designed to address resistance mechanisms. While facing competition from larger pharmaceutical companies developing menin inhibitors such as Syndax, Janssen, and Servier, Kura Oncology aims to maintain a competitive edge through its intellectual property, clinical data, and strategic collaborations.

The company serves patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible NPM1 mutation and no satisfactory alternative treatment options, primarily in the United States. Kura Oncology also targets patients with other genetically defined subsets of acute leukemias, gastrointestinal stromal tumors (GIST), and solid tumors such as renal cell carcinoma, non-small cell lung cancer, colorectal cancer, and pancreatic cancer through its clinical development programs. Its customers include healthcare providers, hospitals, and specialty pharmacies that administer its therapies to eligible patients.